A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma or Ewing-Like Sarcoma

• Status: Recruiting
• Trial end date: 2024-03-02
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find out whether LY2880070 combined with the chemotherapy drug gemcitabine is an effective treatment for Ewing sarcoma or Ewing-like sarcoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Treatments: Gemcitabine

Criteria

Inclusion Criteria:

• Consent/Assent: all patients and/or their parents or legally authorized representatives must sign written informed consent; assent, when appropriate, will be obtained according to institutional guidelines

• Weight/Age: patients must be ≥40 kg at the time of study enrollment, but may be of any age

• Diagnosis: Patients must have histologically documented locally advanced or metastatic disease confirmed at MSK as follows: ° Main cohort: Ewing sarcoma as molecularly defined by an EWSR1 fusion with an ETS-transcription factor family member including FLI1, ERG, ETV1, ETV4, and FEV

Note: Any patient being enrolled into the pilot cohort will be reviewed with study pathologist, Dr. Cristina Antonescu, to ensure the categorization as Ewing-like sarcoma is appropriate.

• Patients must be able to swallow capsules

• Therapeutic options: patient's current disease state must be one which has failed standard cytotoxic chemotherapy including cyclophosphamide/doxorubicin/vincristine and ifosfamide/etoposide

• Disease Status: patients must have measurable disease based on RECIST 1.1

• Performance level: Karnofsky ≥70% for patients >16 years of age and Lansky ≥70 for patients ≤16 years of age

• Prior Therapy: patients may have had no more than 4 prior regimens (including frontline therapy) and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment

Note: Patients who have previously received gemcitabine will be allowed unless they had hypersensitivity or unacceptable toxicity attributed to gemcitabine

• ≥ 21 days must have elapsed after the last dose of cytotoxic or myelosuppressive chemotherapy and patients must have recovered from the acute toxic effects of these agents (other than alopecia)

• ≥ 14 days must have elapsed after radiation therapy, and toxicity related to prior radiation therapy must be recovered to grade ≤ 1

• ≥ 21 days must have elapsed after the last dose of antibody therapy, and toxicity related to prior antibody therapy must be recovered to grade ≤ 1

Organ Function Requirements:

• Adequate bone marrow function defined as:

• Absolute neutrophil count (ANC) ≥ 1500/mm3

• Platelet count ≥ 100,000/mm3

• Hemoglobin ≥ 8 g/dl

• Adequate renal function defined as estimated glomerular filtration (eGFR) rate ≥ 60 mL/min/1.73m2:

• as estimated by CKD-EPI equation for patients ≥ 18 years of age OR

• As estimated by cystatin C for patients < 18 years of age

• Adequate liver function defined as:

• Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 x upper limit of normal for age

• AST or ALT ≤ 2.5 x upper limit of normal for patients without liver metastases

• AST or ALT ≤ 5 x upper limit of normal for patients with liver metastases

• Serum albumin ≥ 2.5 g/dl

• Adequate cardiac function defined as:

• Left ventricular ejection fraction (LVEF) >45% as measured on echocardiogram, cardiac MRI, or MUGA

• QTc < 470 ms on screening 12 lead electrocardiogram

• Pregnancy/Contraception

• Post-menarchal females must have a negative urine or serum pregnancy test at screening and ≤ 24 hours prior to study treatment

• Males or females of reproductive potential must be willing to use a barrier method of contraception throughout the course of the study and for 6 months after completing study treatment

Exclusion Criteria:

• Patients for whom the investigator deems that gemcitabine is not appropriate

• Patients who have an uncontrolled infection

• Central Nervous System (CNS) Metastases

• Patients who have symptomatic central nervous system (CNS) metastases. Note:

patients with treated and asymptomatic CNS metastases are eligible.

• Patients with CNS metastases requiring corticosteroids for management

• If the treatment of CNS disease requires anticonvulsants, the dose must have been stable for ≥ 4 weeks.

• Patients who are pregnant or breast feeding

• Patients who have a history of Torsades de Pointes, carry a diagnosis of congestive heart failure, or have a family history of prolonged QT syndrome

• Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study

• Patients with known hypersensitivity to gemcitabine